The latest HPRA Drug Safety (April 2022) newsletter highlights prescribing and monitoring information for healthcare professionals about the medicines Paxlovid and transmucosal fentanyl. It includes product information updates for Aimovig, Emgality and ibuprofen-containing products.
Available at: https://www.hpra.ie/docs/default-source/publications-forms/newsletters/hpra-drug-safety-newsletter-edition-107.pdf?sfvrsn=5
This edition:
• Paxlovid – interactions between ritonavir component and other medicines leading to clinically significant reactions
• Transmucosal fentanyl – labelling update to mitigate the risks of off-label use, accidental ingestion or unintentional exposure
• Product information updates recommended by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) – Ibuprofen-containing medicines: Acute Generalised Exanthematous Pustulosis (AGEP) – Aimovig (erenumab): constipation and hypersensitivity – Emgality (galcanezumab): hypersensitivity reactions